Five Prime Therapeutics (FPRX) Rating Lowered to Sell at BidaskClub

Five Prime Therapeutics (NASDAQ:FPRX) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a report released on Thursday.

FPRX has been the subject of several other research reports. Citigroup cut their price objective on Five Prime Therapeutics from $60.00 to $44.00 and set a “buy” rating for the company in a report on Monday, August 20th. ValuEngine lowered Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, July 28th. Leerink Swann started coverage on Five Prime Therapeutics in a report on Thursday, September 13th. They set an “outperform” rating and a $24.00 price objective for the company. Wedbush boosted their price objective on Five Prime Therapeutics from $17.00 to $19.00 and gave the stock a “hold” rating in a report on Friday, August 10th. Finally, Wells Fargo & Co cut their price objective on Five Prime Therapeutics from $58.00 to $35.00 and set an “outperform” rating for the company in a report on Thursday, August 9th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the company. Five Prime Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $29.67.

Shares of NASDAQ FPRX opened at $11.57 on Thursday. Five Prime Therapeutics has a 12 month low of $10.35 and a 12 month high of $30.25. The stock has a market cap of $394.73 million, a PE ratio of -2.15 and a beta of 3.23.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.15) by ($0.22). Five Prime Therapeutics had a negative return on equity of 41.52% and a negative net margin of 221.67%. The business had revenue of $5.77 million for the quarter, compared to analysts’ expectations of $7.45 million. As a group, research analysts forecast that Five Prime Therapeutics will post -4.04 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the stock. FMR LLC lifted its position in Five Prime Therapeutics by 1.0% in the 2nd quarter. FMR LLC now owns 5,281,363 shares of the biotechnology company’s stock worth $83,498,000 after buying an additional 52,319 shares during the last quarter. BlackRock Inc. lifted its position in Five Prime Therapeutics by 1.7% in the 3rd quarter. BlackRock Inc. now owns 2,912,138 shares of the biotechnology company’s stock worth $40,536,000 after buying an additional 48,618 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Five Prime Therapeutics by 14.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,189,654 shares of the biotechnology company’s stock worth $18,808,000 after buying an additional 147,904 shares during the last quarter. Victory Capital Management Inc. lifted its position in Five Prime Therapeutics by 3.3% in the 2nd quarter. Victory Capital Management Inc. now owns 1,102,760 shares of the biotechnology company’s stock worth $17,434,000 after buying an additional 35,670 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Five Prime Therapeutics by 6.7% in the 2nd quarter. Northern Trust Corp now owns 394,878 shares of the biotechnology company’s stock worth $6,243,000 after buying an additional 24,838 shares during the last quarter. Institutional investors own 86.40% of the company’s stock.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Recommended Story: How can investors find ex-dividend dates?

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply